CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vie ...

BEAM-302 Topline Data Update March 25, 2026 NASDAQ: BEAM 2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the therapeutic applications and potential of our technology, including with respect to AATD; our plans, and anticipated timing, to advance our programs, including risto-cel, BEAM-103, BEAM-301, BEAM-304 and ...

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therap ...

Group 1 - Crispr Therapeutics Ag (NASDAQ:CRSP) has seen a 16% increase in share price over the past 12 months, with ARK Investment increasing its stake by 8% in Q4, resulting in a $10.5 million position [1] - The company holds a first-mover advantage in the gene editing and gene therapy sectors, with its CRISPR-based treatment already approved by the FDA [2] - Crispr's CASGEVY therapy for severe sickle cell disease and beta-thalassemia is generating revenue through a partnership with Vertex Pharmaceuticals [2] Group 2 - Hedge fund sentiment towards Crispr Therapeutics increased in Q4, with 32 funds holding the stock, up from 31 in the previous quarter [3] - The FDA approved Crispr's CRISPR-Cas9 gene editing therapy for sickle cell disease in December 2023, after nearly six years of clinical trials [3] - The therapy, Casgevy, disrupts the BCL11A gene to promote the production of fetal hemoglobin, providing a functional cure for sickle cell disease, which affects approximately 1 in 365 Black or African American births [3] - The treatment costs about $2.2 million per use but is expected to be a one-time treatment, with potential lifetime healthcare savings estimated between $4 million and $6 million [3] - Crispr retains 40% of profits from the partnership with Vertex, which has invested nearly $1.1 billion to increase its stake in the commercialization of Casgevy [3]

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream.See where she lands on the #Forbes250: America's Greatest Innovators list:https://t.co/S1qgkoTqmt (Photo: Cody Pickens for Forbes) ...

Summary of Editas Medicine FY Conference Call Company Overview - **Company**: Editas Medicine (NasdaqGS:EDIT) - **Focus**: In vivo CRISPR therapeutics, specifically targeting gene editing through intravenous delivery using lipid nanoparticles [4][5] Core Points and Arguments Gene Editing Approach - Editas utilizes CRISPR technology to make edits in non-coding DNA, aiming to upregulate proteins that mitigate disease risks, such as the LDL receptor in their EDIT-401 program [4][5] - The company claims a 90% mean reduction in LDL cholesterol levels across multiple animal species, indicating potential for significant impact on cardiovascular disease management [4][14] Safety Profile - Editas emphasizes the safety of their gene editing approach compared to AAV-based therapies, highlighting the targeted nature of their lipid nanoparticles and the reduced risk of off-target effects [8][10] - The company has developed a robust safety package for EDIT-401, which has been well-received by regulatory agencies [25][26] Lead Program: EDIT-401 - EDIT-401 targets LDL cholesterol reduction, with preclinical data showing consistent 90% reductions across various animal models [18][19] - The program is based on leveraging genetic insights from human databases to identify gain-of-function variants that enhance LDL receptor expression [15][16] Durability and Efficacy - Preliminary data suggests durability of effect, with ongoing studies to confirm long-term outcomes [24] - The company aims to demonstrate superior efficacy compared to current standard treatments in their upcoming Phase 1 study [30] Patient Population and Market Opportunity - Initial target population includes patients with heterozygous familial hypercholesterolemia (HeFH), a high-risk group for cardiovascular disease [37][38] - The broader addressable market includes approximately 10 million patients in the U.S. who are unable to achieve target cholesterol levels with existing therapies [38][47] Future Pipeline and Strategy - Editas plans to expand its pipeline beyond EDIT-401, focusing on additional non-coding edits to upregulate rescue proteins [58][59] - The company is committed to maintaining a strong focus on executing the EDIT-401 program while exploring new therapeutic avenues [59] Important but Overlooked Content - Editas has a strong partnership with Genevant for liver delivery, which enhances their delivery technology and reduces risk [36][61] - The company has a cash runway extending into Q3 of 2027, with $146 million in cash at the end of 2025, providing confidence in meeting upcoming milestones [63] - Key upcoming catalysts include early human proof of concept data, non-clinical and CMC data, and the potential clearance of CTA/IND [64]

Financial Performance - CRISPR Therapeutics reported total revenue of $116 million for FY2025, with $54 million generated in Q4 alone, driven by a nearly threefold increase in patient initiations compared to the previous year [1][6] - A total of 147 patients have started treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East [1] Product Development - The company is advancing a diverse 'in vivo' liver editing portfolio using lipid nanoparticles, with key programs including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials in mid-2026 [2] - CRISPR is collaborating with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases, with Phase 2 data for their lead Factor XI candidate expected in H2 2026 [3] - The clinical pipeline includes 'zugo-cel,' a CAR-T cell therapy for autoimmune diseases and B-cell cancers, and CTX213, an islet cell replacement candidate for Type 1 diabetes showing promising preclinical efficacy [3] Technology and Innovation - CRISPR Therapeutics utilizes its Cas9 platform to develop gene-based medicines for serious human diseases [4]

Summary of Prime Medicine Conference Call Company Overview - **Company**: Prime Medicine (NasdaqGM:PRME) - **Event**: Citi's Life Sciences Conference - **Date**: March 11, 2026 Key Highlights and Core Points Clinical Programs - Prime Medicine is on the verge of entering the clinic with its first two in vivo programs targeting Wilson's disease and alpha-1 antitrypsin deficiency (AATD), with clinical data expected in 2027 [4][6] - The company has existing clinical data from an ex vivo program in chronic granulomatous disease [4][6] Regulatory Strategy - The company plans to submit a Biologics License Application (BLA) for its chronic granulomatous disease program, with a focus on enrolling one more pediatric patient [10][11] - The estimated cost for the BLA submission has significantly decreased from $50 million-$100 million to a much smaller fraction due to FDA flexibility in requirements [13] Unmet Medical Needs - There is a significant unmet need in Wilson's disease, with 20-30% of patients still progressing despite adherence to standard care [18][19] - Prime Medicine's approach aims to provide a more effective treatment option compared to existing therapies, which do not cure the disease [23][24] Competitive Landscape - In the AATD space, Prime Medicine's gene editing technology is positioned as the only modality that can restore the wild-type protein by fixing the mutation at the DNA level [52][53] - The company acknowledges competition but emphasizes the unique benefits of its Prime Editing approach over other gene therapies [51][52] Patient Population and Market Potential - The initial target mutation for Wilson's disease (H1069Q) affects approximately 30%-50% of the Caucasian population, with plans to address additional mutations globally [45][46] - The company aims to treat a significant portion of the global patient population, with a focus on early intervention to prevent disease onset [46][47] Safety and Delivery - Prime Medicine's lipid nanoparticle (LNP) delivery system has shown a wider therapeutic index in preclinical studies, indicating a favorable safety profile [58][59] - The technology is designed to minimize off-target effects, which is a common concern in CRISPR therapies [59] Additional Important Insights - The company is optimistic about the potential for its therapies to significantly improve patient outcomes, although it remains cautious about using the term "cure" due to the complexity of the diseases involved [42][43] - The regulatory pathway is still evolving, and Prime Medicine aims to be a trailblazer in the gene editing space, potentially leading to expedited approvals based on strong clinical data [44] This summary encapsulates the critical points discussed during the conference call, highlighting Prime Medicine's strategic direction, clinical programs, and the broader implications for the gene editing landscape.

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is recognized as one of the 10 most shorted biotech stocks to consider for investment by hedge funds [1] - Morgan Stanley raised its price target for CRISPR Therapeutics from $32 to $33 while maintaining an Underweight rating [1] - Needham increased its price target from $80 to $82, maintaining a Buy rating, indicating over 45% upside potential [2] Financial Performance - Casgevy, a therapy developed by CRISPR's partner Vertex Pharmaceuticals, generated $116 million in sales in 2025, exceeding the previous target of approximately $100 million [2] - The strong sales performance of Casgevy indicates early commercial traction and supports a positive outlook for CRISPR Therapeutics [2] Company Overview - CRISPR Therapeutics is a gene editing company focused on developing potentially curative medicines for serious diseases, including sickle cell disease and blood disorders [3] - The company's broader pipeline also addresses cancer, autoimmune conditions, and diabetes, positioning it as a leader in the future of genetic medicine [3]

Core Insights - Precision BioSciences presented preclinical data for PBGENE-DMD, highlighting its potential for durable dystrophin expression and functional benefits in treating Duchenne muscular dystrophy (DMD) [1] - The data indicates that PBGENE-DMD could potentially treat up to 60% of DMD patients by restoring near full-length functional dystrophin protein through permanent gene correction [1] Group 1: Preclinical Data Findings - PBGENE-DMD treatment in a humanized DMD mouse model showed improvements in muscle pathology and biomarkers of muscle damage, with a 50-65% reduction in CK levels at 90 days post-treatment [1] - Treated mice maintained approximately 81% to 84% of maximal force output and 89% to 92% of tetanic force output compared to healthy mice over a nine-month period [1] - Evidence of therapeutic levels of functional dystrophin protein was observed in both skeletal and cardiac muscle, with increasing levels over time [1] Group 2: Treatment Mechanism and Design - PBGENE-DMD utilizes a gene excision approach, differentiating it from existing treatments like microdystrophin and exon skipping [1] - The therapy targets muscle satellite cells, which are essential for muscle regeneration, potentially providing long-term benefits [1] - The treatment is designed for DMD patients with mutations in exons 45-55, representing a significant portion of the patient population [1] Group 3: Clinical Trial and Regulatory Status - The Phase 1/2 FUNCTION-DMD clinical trial is set to enroll ambulatory DMD patients aged 2-7 with specific mutations, focusing on safety, tolerability, and efficacy [1] - PBGENE-DMD has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, facilitating its development and potential market entry [1]